Citations

Showing 10 of 108104 citations.

Sellar Region Atypical Teratoid/Rhabdoid Tumors in Adults: Clinicopathological Characterization of Five Cases and Review of the Literature
Paolini, Michael A., Kipp, Benjamin R. , Sukov, William R. , Jenkins, Sarah M. , Aranda, Derick, SantaCruz, Karen S., Al‐Dandan, Sadeq , Fisher, P. H., McDonald, William C. , Bondurant, Charles P., Darkow, G. V. D., Parisi, Joseph E. , Jentoft, Mark E. , Raghunathan, Aditya , Barr Fritcher, Emily G, Raghunathan, Aditya , Fritcher, Emily G. Barr , McDonald, William C, Giannini, Caterina

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | October 5, 2018 | Volume: 77 | Issue: 12 | Pages: 1115-1121

10.1093/jnen/nly091 | PMID 30295777 Get It

Letter: identifying coeliac disease among patients with bloating—Authors' reply
Hujoel, Isabel A. , Rubio-Tapia, Alberto, Rubio‐Tapia, Alberto

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 5, 2018 | Volume: 48 | Issue: 8 | Pages: 883-883

10.1111/apt.14964 | PMID 30281830 Get It

Linked ContentThis article is linked to Hujoel et al and Ellul papers. To view these articles visit https://doi.org/10.1111/apt.14625 and https://doi.org/10.1111/apt.14918.
Case-based review: atypical teratoid/rhabdoid tumor
Rao, Amulya A. Nageswara , Raghunathan, Aditya , Biegel, Jaclyn A. , Nesvick, Cody L. , Raghunathan, Aditya , Daniels, David J.

Mayo Clinic

Neuro-Oncology Practice | October 5, 2018 | Volume: 6 | Issue: 3 | Pages: 163-178

10.1093/nop/npy037 | PMID 31386032 Get It

AbstractAtypical teratoid/rhabdoid tumor (AT/RT) is a rare CNS cancer that typically occurs in children younger than 3 years of age. Histologically, AT/RTs are embryonal tumors that contain a rhabdoid component as well as areas with primitive neuroectodermal, mesenchymal, and epithelial features. Compared to other CNS tumors of childhood, AT/RTs are characterized by their rapid growth, short symptomatic prodrome, and large size upon presentation, often leading to brain compression and intracranial hypertension requiring urgent intervention. For decades, the mainstay of care has been a combination of maximal safe surgical resection followed by adjuvant chemotherapy and radiotherapy. Despite advances in each of these modalities, the relative paucity of data on these tumors, their inherently aggressive course, and a lack of molecular data have limited advances in treatment over the past 3 decades. Recent large-scale, multicenter interdisciplinary studies, however, have significantly advanced our understanding of the molecular pathogenesis of these tumors. Multiple clinical trials testing molecularly targeted therapies are underway, offering hope for patients with AT/RT and their families.
Heart transplantation for infective endocarditis: Viable option for a limited few?
Murphy, Katie , Vikram, Holenarasipur R. , Murphy, Katie M , Vikram, Holenarasipur R.

Mayo Clinic

Transplant Infectious Disease | October 5, 2018 | Volume: 21 | Issue: 1 | Pages: No page available

10.1111/tid.13006 | PMID 30281879 Get It

AbstractActive infection in the recipient is considered a relative contraindication for solid organ transplantation. However, heart transplantation (HT) can be curative in patients with ventricular assist device infections. For patients with infective endocarditis (IE), valve replacement is part of the management strategy based on emergent, acute, or elective indications. HT has been utilized as an uncommon and sporadic treatment option for carefully selected patients with refractory or recurrent IE after all other surgical treatment options have been exhausted or are not feasible. Herein, we review 19 published cases of IE in whom HT was undertaken in the setting of ongoing active infection with reported good outcomes. We attempt to propose general criteria for HT in the setting of IE and discuss challenges and hurdles that clinicians might encounter when considering HT for active IE in the absence of robust data or clearly defined criteria.
Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome
Mauras, Nelly , Torres‐Santiago, Lournaris , Santen, Richard, Ross, Judith L. , Colón‐Otero, Gerardo , Damaso, Ligeia, Hossain, Jobayer , Wang, Qingqing , Mesaros, Clementina , Mericq, Verónica , Blair, Ian A.

Mayo Clinic

Clinical Endocrinology | October 5, 2018 | Volume: 90 | Issue: 1 | Pages: 155-161

10.1111/cen.13869 | PMID 30281805 Get It

AbstractObjectiveThe established link between oestrogen and breast cancer occurs via both oestrogen receptor (ER)‐mediated and non ER‐mediated mechanisms. The term genotoxic estrogens describes mutagenic metabolites, including oestrogen catechols and quinones, which have been linked to breast carcinogenesis in post‐menopausal women. We aimed to assess whether the route of administration of 17β oestradiol (E2) affects the accumulation of genotoxic oestrogen metabolites in a model of ovarian failure in young girls with Turner syndrome.MethodsStored plasma samples obtained at 0 and 12 months were used from 40 adolescents with Turner syndrome who participated in a 12 months randomized controlled trial of the metabolic impact of E2 orally (2 mg/d) vs transdermally (100 µg/d); dose escalation allowed matching of unconjugated E2 levels in the parent study. We measured 12 oestrogen metabolites (total concentrations = conjugated and unconjugated) using a highly sensitive LCMSMS assay. Results from 48 normally menstruating adolescents were used for comparison.ResultsAfter treatment, least square mean (SE) total E2 concentrations were higher in the oral vs transdermal group (6784 pmol/L vs 1123 [1614], P < 0.0001), as was oestrone (E1) (91 060 pmol/L vs 19 278 [16 534], P < 0.0001). Also, higher after oral treatment were catechol‐oestrogens 4‐hydroxy‐E2 (149 vs 28 [±49] pmol/L), 2‐hydroxy‐E2 (300 vs 76 [±52]), 4‐hydroxy‐E1 (450 vs 105 [±113]), 2‐hydroxy‐E1 (3094 vs 740 [±684]) and 16α‐hydroxy‐E1 (3,007 vs 157 [±534]) (<0.001 between groups). Levels were much closer to controls in the transdermal group.ConclusionsCommon feminizing doses of oral oestradiol for 12 months result in substantial accumulation of unphysiologic, genotoxic oestrogens compared to transdermal oestradiol, expanding concerns about oral oestrogens’ first hepatic passage. Further studies assessing long‐term risks of these metabolites in women taking different forms of oestrogen are needed.
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and management
Tefferi, Ayalew , Barbui, Tiziano , Barbui, Tiziano

Mayo Clinic

American Journal of Hematology | October 5, 2018 | Volume: 94 | Issue: 1 | Pages: 133-143

10.1002/ajh.25303 | PMID 30281843 Get It

Abstract Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation. Diagnosis: Bone marrow morphology remains the cornerstone of diagnosis. In addition, the presence of JAK2 mutation is expected in PV while approximately 90% of patients with ET express mutually exclusive JAK2, CALR, or myeloproliferative leukemia mutations. In ET, it is most important to exclude the possibility of prefibrotic myelofibrosis. Survival: Median survivals are 14 years for PV and 20 years for ET; the corresponding values for younger patients are 24 and 33 years. Certain mutations (mostly spliceosome) and abnormal karyotype might compromise survival in PV and ET. Life‐expectancy in ET is inferior to the control population. Driver mutations have not been shown to affect survival in ET. Risk of thrombosis is higher in JAK2‐mutated ET. Leukemic transformation rates at 10 years are estimated at <1% for ET and 3% for PV. Thrombosis Risk: In PV, 2 risk categories are considered: high (age > 60 years or thrombosis history present) and low (absence of both risk factors); in ET, 4 risk categories are considered: very low (age ≤ 60 years, no thrombosis history, JAK2 wild‐type), low (same as very low but JAK2 mutation present), intermediate (age > 60 years, no thrombosis history, JAK2 wild‐type) and high (thrombosis history present or age > 60 years with JAK2 mutation). Risk‐Adapted Therapy: The main goal of therapy in both PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once‐ or twice‐daily aspirin (81 mg), in the absence of contraindications. Very low‐risk ET might not require therapy while aspirin therapy is advised for low‐risk disease. Cytoreductive therapy is recommended for high‐risk ET and PV but it is not mandatory for intermediate‐risk ET. First‐line drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second‐line drugs of choice are interferon‐α and busulfan. We do not recommend treatment with ruxolutinib in PV, unless in the presence of severe and protracted pruritus or marked splenomegaly that is not responding to the aforementioned drugs.
Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis
Tefferi, Ayalew , Shah, Sahrish, Reichard, Kaaren K. , Hanson, Curtis A. , Pardanani, Animesh

Mayo Clinic

American Journal of Hematology | October 5, 2018 | Volume: 94 | Issue: 1 | Pages: No page available

10.1002/ajh.25302 | PMID 30281840 Get It

Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)
Hsiao, Edward C. , Rocco, Maja Di , Cali, Amanda, Zasloff, Michael , Mukaddam, Mona Al , Pignolo, Robert J. , Grunwald, Zvi, Netelenbos, Coen , Keen, Richard , Brown, Matthew A. , Cunto, Carmen De , Delai, Patricia , Haga, Nobuhiko , Morhart, Rolf, Scott, Christiaan , Zhang, Keqin , Diecidue, Robert J. , Friedman, Clive, Kaplan, Frederick S. , Eekhoff, Elisabeth M. W. , Hsiao, Edward C , Baujat, Geneviève , Cho, Tae‐Joon , Brown, Matthew , Kaplan, Frederick S

Mayo Clinic

British Journal of Clinical Pharmacology | October 5, 2018 | Volume: 85 | Issue: 6 | Pages: 1199-1207

10.1111/bcp.13777 | PMID 30281842 Get It

Clinical trials for orphan diseases are critical for developing effective therapies. One such condition, fibrodysplasia ossificans progressiva (FOP; MIM#135100), is characterized by progressive heterotopic ossification (HO) that leads to severe disability. Individuals with FOP are extremely sensitive to even minor traumatic events. There has been substantial recent interest in clinical trials for novel and urgently‐needed treatments for FOP. The International Clinical Council on FOP (ICC) was established in 2016 to provide consolidated and coordinated advice on the best practices for clinical care and clinical research for individuals who suffer from FOP. The Clinical Trials Committee of the ICC developed a focused list of key considerations that encompass the specific and unique needs of the FOP community – considerations that are endorsed by the entire ICC. These considerations complement established protocols for developing and executing robust clinical trials by providing a foundation for helping to ensure the safety of subjects with FOP in clinical research trials.
Ustekinumab Is Effective for the Treatment of Crohn’s Disease of the Pouch in a Multicenter Cohort
Weaver, Kimberly N. , Gregory, Martin , Syal, Gaurav , Hoversten, Patrick , Hicks, Stephen B., Patel, Devin , Christophi, George P. , Beniwal‐Patel, Poonam , Isaacs, Kim L. , Raffals, Laura E. , Deepak, Parakkal , Hicks, Stephen Bradley, Raffals, Laura, Deepak, Parakkal , Herfarth, Hans , Barnes, Edward L.

Mayo Clinic

Inflammatory Bowel Diseases | October 5, 2018 | Volume: 25 | Issue: 4 | Pages: 767-774

10.1093/ibd/izy302 | PMID 30295784 Get It

Út a Városmajortól a Mayo Klinikáig. Önéletrajzi összegzés a „Száz éve született Dr. Soltész Lajos” emlékszimpóziumon, Budapesten 2017. november 24-én elhangzott előadás alapján
Gloviczki, Péter , Gloviczki, Péter

Mayo Clinic

Orvosi Hetilap | October 5, 2018 | Volume: 159 | Issue: 32 | Pages: 1326-1331

10.1556/650.2018.ho2606 | PMID 30078358 Get It